27f76511-b825-41a5-a0b5-257c80223d8b
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MYC_TARGETS_V1+0.500
- MITOTIC_SPINDLE+0.400
- MYC_TARGETS_V2+0.400
- ANDROGEN_RESPONSE+0.300
- ANGIOGENESIS+0.300
- MTORC1_SIGNALING+0.300
- MYOGENESIS+0.300
- TGF_BETA_SIGNALING+0.300
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.300
- COAGULATION-0.300
- BILE_ACID_METABOLISM-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- KRAS_SIGNALING_DN-0.200
- NOTCH_SIGNALING-0.200
- PANCREAS_BETA_CELLS-0.200
- APICAL_SURFACE-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- HEDGEHOG_SIGNALING-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934852 | — | — | 0.844 |
| 2 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.831 |
| 3 | 040cf8cf-7b9d-4873-a51d-ba13bba4201a | — | — | 0.821 |
| 4 | HLF_LIVER | HCC | — | 0.812 |
| 5 | SRR934804 | — | — | 0.801 |
| 6 | TCGA-91-6848-01A-11R-1949-07 | — | cohortA1 | 0.797 |
| 7 | SRR934813 | — | — | 0.794 |
| 8 | SRR934902 | — | — | 0.793 |
| 9 | s0122158 | — | — | 0.786 |
| 10 | SRR934935 | — | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |